Neurocrine Biosciences (NBIX) EPS (Weighted Average and Diluted) (2010 - 2026)

Neurocrine Biosciences has reported EPS (Weighted Average and Diluted) for 17 years, with the latest figure at $1.91 in Q1 2026.

• For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 2287.5% year-over-year to $1.91; the trailing twelve-month figure through Mar 2026 stood at $6.49 (up 120.0% YoY), and the FY2025 full-year result was $4.67, up 41.95% from the prior year.
• EPS (Weighted Average and Diluted) for Q1 2026 stood at $1.91, up from $1.48 in the prior quarter.
• The five-year high for EPS (Weighted Average and Diluted) was $2.04 in Q3 2025, with the low at -$0.79 in Q1 2023.
• Historically, EPS (Weighted Average and Diluted) has averaged $0.81 across 5 years, with a median of $0.89 in 2022.
• Annual changes were most pronounced in 2023 — EPS (Weighted Average and Diluted) sank 664.29% — and 2026, when it soared 2287.5%.
• Neurocrine Biosciences' EPS (Weighted Average and Diluted) stood at $0.89 in 2022, then surged by 64.04% to $1.46 in 2023, then sank by 31.51% to $1.0 in 2024, then surged by 48.0% to $1.48 in 2025, then gained by 29.05% to $1.91 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $1.91 (Q1 2026), $1.48 (Q4 2025), and $2.04 (Q3 2025), per Business Quant data.